Biotech | March 11, 2022
First-in-human trial in US for Gan & Lee type 2 diabetes drug
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
Breakthrough formulation helps reduce the risk of exposure using a non-hazardous formulation and leakproof format during transport and processing
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
The team built a multiple ionic device system, each of which had a lithium cobalt oxide channel arranged on a common lithium phosphorus oxynitride electrolyte
As a part of its CSR initiatives, the ‘Healthcare Heroes of India’ Awards by Metropolis aims to identify and recognize those individuals and institutions in healthcare sector with a strong sense of purpose and commitment towards patient care and who have prioritized it over all other growth parameters
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Subscribe To Our Newsletter & Stay Updated
